<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>23-ALFUZOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. 

.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>23-ALFUZOSIN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPVIR" code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the alfuzosin by decrease of its hepatic metabolism by the therapy with the two medications.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
